An Alumni of JLABS South San Francisco, Senti is organized around addressing the field of Hematologic Malignancies. With a assembled team of engineers and scientists, the effort is usefully described as that of leveraging synthetic biology to treat the most pressing diseases. Principals of the firm suggest that cancer and autoimmune diseases - by definition, inherently complex diseases -- require innovative, more intelligent medicines that have therapeutic effect but - usefully - also include being able to sense cues in the disease environment and respond to these cues in a regulated manner. Describing what they do as "outsmarting complex diseases with more intelligent medicines" the firms proprietary synthetic biology platform is structured to provide fundamental advantages for therapeutics development to enable design of adaptive therapies for challenging diseases - a gene circuit repertoire that can be used to create more effective, better tolerated cell and gene therapies that can respond to such factors as disease severity and changes in the microenvironment.